PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $0.93, for a total transaction of $38,595.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of PURE Bioscience (PURE) opened at $0.90 on Monday. PURE Bioscience has a 12 month low of $0.83 and a 12 month high of $1.36. The company has a market cap of $61.18, a price-to-earnings ratio of -8.18 and a beta of -1.48.
PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.02). PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.65 million. equities analysts predict that PURE Bioscience will post -0.08 EPS for the current year.
Separately, ValuEngine raised shares of PURE Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/15/insider-selling-pure-bioscience-pure-ceo-sells-38595-00-in-stock.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.